Displaying 1 - 10 of 10

Display:

12 24 48

Liver Tumours

5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View

Liver Tumours

5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View

Liver Tumours

5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View

Liver Tumours

5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View

Liver Tumours

5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View

Metabolism, Alcohol & Toxicity

5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View

Metabolism, Alcohol & Toxicity

5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View

Metabolism, Alcohol & Toxicity

5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View

Metabolism, Alcohol & Toxicity

5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View

Metabolism, Alcohol & Toxicity

5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View

Displaying 1 - 10 of 10

Display:

12 24 48